Muhammad Junaid Tariq

Hematology-Oncology Physician, Interested in Lymphoma/BMT/cell therapy | Alum @roswellpark @cookcountyIMR

[Hamza Hashmi @hhashmi87]

If you are looking for a high-level summary (20 min) of key #MultipleMyeloma abstracts presented at #ASCO2026, this will be great resource. #MedEd #Medtwitter #MMSM @VuMedi #BestofASCO

[Uriel Suárez @UsuarezMD]

Hodgkin lymphoma #EHA2026

[Toby Eyre @tobyeyre82]

Grateful to @DrJFriedberg for an hugely insightful editorial in @JCO #EHA2026

End of Methotrexate for CNS Prophylaxis in Diffuse Large B-Cell Lymphoma | Journal of Clinical Oncology https://t.co/Z2hMvGNC8b

[GELTAMO @geltamo]

Diagnosis of primary CNS lymphoma through molecular and immune biomarkers in cerebrospinal fluid (PRICELUS): a multicentre, prospective, cohort study - The Lancet Haematology https://t.co/klJbWpMKBD

[John P. Leonard, MD @JohnPLeonardMD]

Great to have ongoing trials of this approach @nyulangone @nyugrossman Kidney Transplantation in Two Highly Sensitized Candidates after CAR T-Cell Therapy | New England Journal of Medicine https://t.co/7o6Q16d9W9

[Toby Eyre @tobyeyre82]

#EHA2026 LBA
Primary results of BRUIN CLL322
FD Pirto-VenR vs VenR
80% cBTKi exposed
2Y PFS PVR 86.9% vs VR 71.8%
Subgroups of TP53 & PD on cBTKi marked ⬆️PFS
Substantial ⬆️ in PFS with little added tox.
Practice changing trial in R/R #CLL
#pirtobrutinib #BRUINCLL322 #EHA2026

[Talha Badar @TalhaBadarMD]

#ASCO26 #AML #leusm

Does venetoclax duration matter in frontline HMA+Ven for AML?

Poster: In a @MayoCancerCare analysis of 540 newly diagnosed AML patients, outcomes were driven primarily by disease biology, not venetoclax duration. Led by Dr. Naseema Gangat 👏👏👏

🔹 Similar OS across 7-, 14-, 21-, and 28-day schedules
🔹 Comparable outcomes within ELN 2024 and Mayo genetic risk groups
🔹 Higher early mortality with shorter durations likely reflected selection of frailer patients
🔹 In ELN high-risk AML, 14-day venetoclax was associated with inferior survival compared with 21- and 28-day schedules

Take-home: Venetoclax duration should be individualized based on genetics, response, cytopenias, and patient fitness rather than a one-size-fits-all approach.

[Muhammad Junaid Tariq @MuhammadJTariq]

@DrMMurphy Congratulations a lot 🎉🎉🎉

[Martina Murphy, MD @DrMMurphy]

Powerful presidential address by Dr. Eric Small at #ASCO26. The charge could not be clearer. Discovery without translation is an incomplete promise. The science has to make it to the clinic, to the bedside, to our patients and in the ways that matter most to them.

For every patient. Every cancer. Everywhere.

@ASCOPres @UFHealthCancer

[Muhammad Junaid Tariq @MuhammadJTariq]

@waraonc23 @HannahRAbrams @yoshi735 @MayoHemeOnc Don’t lose heart. Every failure teaches us a lesson and would eventually lead to success. Looking forward to read and learn from your viewpoint.

[Ajay Major, MD, MBA @majorajay]

RW bispecific outcomes R/R FL (CUBIC Consortium) #ASCO26
- 99 pts, median 3 prior lines, 15% prior CAR
- ORR 87%, CRR 72%
- 1-yr PFS 72%, 18-mo OS 92%
- PFS not affected by BsAb type or prior CAR
- outcomes similar for older/very elderly pts
- CRS 34% (mostly G1, no G3+), ICANS 3% (all G1)
Encouraging data for BsAb across diverse/heavily pretreated FL, including older adults. #lymsm #geriheme
https://t.co/Mb67UxWYeK

[Ajay Major, MD, MBA @majorajay]

Hans IHC vs GEP for DLBCL COO classification #EHA2026
Large meta-analysis (19 studies, 2247 tumors) to eval noninferiority of Hans IHC to GEP.
Estimated accuracy:
- Hans IHC 90%
- pooled GEP 95%
- 4.5% difference met noninferiority margin
- sens 6.5% / NPV 6.4%
Supports Hans IHC as a practical & reliable procedure for COO classification in DLBCL. Particularly important with pola non-GC data. #lymsm cc @AshAlizadeh @gvencut1
https://t.co/NA59xg9kuY

[Eddie Cliff @Eddie_Cliff]

Do you need to get your patient with myeloma into CR prior to autologous transplant?

Answers to this and many other key questions in newly diagnosed myeloma with the eloquent and wise @VincentRK on @BloodCancerTalk - wherever you get your podcasts
#mmsm #myeloma @rajshekharucms

[Rahul Banerjee, MD, FACP @RahulBanerjeeMD]

#COMy2026 still one of the most fascinating cases I’ve ever seen, now being presented by @H_Einsele:

Primary refractoriness to teclistamab reversed purely by plasmapheresis to knock down sBCMA and give bsAbs a chance to work. Fascinating correlative work by 🇩🇪 group!

[calliecoombs @calliecoombsmd]

Well dang I didn’t realize this was coming so quickly, wonder if this will bring up awkward off-label conversations in CLL (so far I would only use on trial). But great to have new MCL option!! #cllsm

[Bishal Gyawali, MD, PhD, FASCO @oncology_bg]

This is all the advice I got.

https://t.co/WtWKz1SPZN

[Anita Afzali MD, MPH, MHCM, FACG, AGAF @IBD_Afzali]

Healthcare rewards activity, Strategy rewards direction ~@ibdtweets

Excellent talk on Strategic Thinking & Navigating complex health systems and impactful leadership

💡 what's the problem to solve
⏰️ dedicate time to build strategic focus
🤝 #FindYourFriendtors
#SNH2026

[Chuan Chen, MD PhD @DrChuanChen]

I am thrilled to share that our work on the real-world utility of lymphoma NGS has been published in @Human_Pathology . Many thanks to Dr. King and Dr. He for their incredible mentorship on this project. @MayoClinicPath
https://t.co/5nkxuFq0qI

[Faiz Anwer MD @FaizAnwerMD1]

I put together a free guide on using AI the right way in medicine. How to use it as a teacher. Where the ethical line is. 45+ research databases. Formal AI courses from AMA, AAMC, Harvard, Stanford. For medical students, IMGs, residents, and fellows:
https://t.co/DomyhcVGfC

[Uriel Suárez @UsuarezMD]

Infections after bispecific antibodies in B-cell lymphomas | Blood Advances | American Society of Hematology https://t.co/SqrXbCCrbt